Search Results
ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
Dr. Piccart on the Implications of the HERA Trial
Dr. Martine Piccart on HER2-targeted therapies in breast cancer
Time for change: introducing genomic predictors in ER+ breast cancer
HER2 Positive Breast and Stomach Cancer Treatment Herceptin (trastuzumab)
Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast Cancer
Martine Piccart, MD, PhD: Can Patients and Advocates Help With Tissue and Biospecimen Collection?
AACR Scientific Podcasts: Interview with Dr. Martine Piccart at 2009 SABCS
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
Martine Piccart-Gebhart
Precision medicine: l’opinione di Martine Piccart
Highlights and goals of IMPAKT 2012: Prof Martine Piccart
